We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Olympus

Manufactures optical and digital equipment for the healthcare and consumer electronics sectors, including endoscopy a... read more Featured Products: More products

Download Mobile App




AI-Based Pathology Diagnostic Tool for Gastric Cancer Achieves 100% Sensitivity in Trials

By LabMedica International staff writers
Posted on 29 Nov 2021

Olympus Life Science (Waltham, MA, USA) has announced the results of its ongoing joint research program to create an AI-based pathology diagnostic tool with the potential to streamline pathologists’ workloads. More...

The diagnostic tool achieved 100% sensitivity and 50% or more specificity for all gastric biopsy pathology specimens analyzed.

The ongoing shortage of pathologists has led to a demand for AI-based pathology diagnostic tools. Olympus, through its Office of Innovation, began developing an AI-based pathology diagnostic tool. In the initial testing phase, the AI was trained using 368 gastric biopsy pathology slide images. The second phase of research began in November 2020, when the diagnostic tool was expanded to six hospitals in Japan, with the aim of verifying the versatility and improving the accuracy of the AI tool. Specifically, it was important to test whether the tool works correctly on pathology slides that vary in thickness and color. The goal of this program is to deliver AI pathology diagnosis software that can assist pathologists by 2023.

The AI-based pathology tool uses a convolutional neural network6 (CNN) optimized to analyze pathology images. This technology enables the tool to identify adenocarcinoma7 versus non-adenocarcinoma tissue in an image. Once the AI was trained, it was tested using 1200 pathology whole slide images from the six institutions participating in the study. The AI classified each image as either adenocarcinoma or non-adenocarcinoma. The AI tool was able to achieve 100% sensitivity and 50% or higher specificity for slides from all six facilities. The robustness of the results will enable Olympus to pursue commercialization of the AI tool in the future.

Related Links:
Olympus Life Science 


Gold Member
Hematology Analyzer
Medonic M32B
Collection and Transport System
PurSafe Plus®
Capillary Blood Collection Tube
IMPROMINI M3
Gold Member
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: When assessing the same lung biopsy sample, research shows that only 18% of pathologists will agree on a TCMR diagnosis (Photo courtesy of Thermo Fisher)

Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection

Lung transplant recipients face a significant risk of rejection and often require routine biopsies to monitor graft health, yet assessing the same biopsy sample can be highly inconsistent among pathologists.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.